NCT03023124View on ClinicalTrials.gov

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 4, 2018

Primary Completion Date

December 6, 2024

Study Completion Date

December 6, 2024

Conditions

Solitary Fibrous Tumors

Interventions

DRUG

Trabectedin

Treatment with trabectedin repeated every 21 days for 6 cycles

DRUG

Adriamycin

Treatment with Adriamycin at day 1 every 21 days for 6 cycles

DRUG

Dacarbazine

Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles

Trial Locations (6)

10060

Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -, Candiolo

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

40136

IRCCS Istituto ortopedico Rizzoli, Bologna

59100

Nuovo Ospedale di Prato, Prato

00128

Policlinico Universitario Campus Biomedico, Roma

Unknown

Ospedale Giaccone, Palermo

All Listed Sponsors

lead

Italian Sarcoma Group

NETWORK

NCT03023124 - Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor | Biotech Hunter | Biotech Hunter